Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous Hodgkin's disease

M R Morman, J W Petrozzi

    Cutis
    |November 1, 1980
    PubMed
    Summary

    Cutaneous involvement in Hodgkin's disease, characterized by severe itching and skin lesions, does not always indicate a poor prognosis. Effective treatments are available for managing these skin manifestations in cancer patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.

    Journal of the American Academy of Dermatology·1998
    Same author

    Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail.

    Journal of the American Academy of Dermatology·1998
    Same author

    Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.

    Journal of the American Academy of Dermatology·1998
    Same author

    Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail.

    Journal of the American Academy of Dermatology·1998
    Same author

    Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis.

    International journal of dermatology·1998
    Same author

    Ofloxacin versus cephalexin for treating skin and soft tissue infections.

    International journal of dermatology·1992

    Area of Science:

    • Oncology
    • Dermatology
    • Clinical Case Study

    Background:

    • Hodgkin's disease is a malignancy of the lymphatic system.
    • Cutaneous manifestations can occur in patients with Hodgkin's disease.
    • The prognostic significance of skin involvement in Hodgkin's disease requires further elucidation.

    Observation:

    • A patient with a history of Hodgkin's disease presented with significant pruritus and various skin lesions.
    • These cutaneous symptoms were associated with the underlying malignancy.
    • The patient demonstrated a favorable clinical course for over seven years despite skin involvement.

    Findings:

    • Cutaneous involvement in Hodgkin's disease is not invariably linked to a poor prognosis.
    • The patient's long-term survival suggests that skin manifestations can be managed effectively.
    • Systemic chemotherapy and topical therapies can be beneficial for managing skin lesions.

    Implications:

    • Clinicians should recognize that skin involvement in Hodgkin's disease may not be a dire prognostic sign.
    • Aggressive management of cutaneous symptoms can improve patient quality of life.
    • Further research into the relationship between skin manifestations and Hodgkin's disease outcomes is warranted.

    Related Experiment Videos